Fatostatin inhibits the tumor growth of pancreatic cancer by targeting SREBP1 and lipid synthesis

Cancan Zhou; Cancan Zhou; Zhengdong Jiang; Zhengdong Jiang; Xin Chen; Xin Chen; Ke Chen; Ke Chen; Zheng Wu; Zheng Wu; Qingyong Ma; Qingyong Ma; Xuqi Li; Xuqi Li

doi:10.18632/oncotarget.24224

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 01/13/2018.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

Fatostatin inhibits the tumor growth of pancreatic cancer by targeting SREBP1 and lipid synthesis

Cancan Zhou _, Cancan Zhou, Zhengdong Jiang, Zhengdong Jiang, Xin Chen, Xin Chen, Ke Chen, Ke Chen, Zheng Wu, Zheng Wu, Qingyong Ma, Qingyong Ma, Xuqi Li and Xuqi Li _

Cancan Zhou1, Zhengdong Jiang1, Xin Chen1, Ke Chen1, Zheng Wu1, Qingyong Ma1 and Xuqi Li2

1 Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China

2 Department of General Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China

Correspondence to:

Qingyong Ma, email: [email protected]

Xuqi Li, email: [email protected]

Keywords: SREBP1; fatostatin; lipid synthesis; proliferation; pancreatic cancer

Received: February 27, 2017 Accepted: December 05, 2017 Epub: January 13, 2018

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24224

Publication Alerts

Oncoscience

Post-Publication Promotion

Withdrawal Notice

Research Papers:

Fatostatin inhibits the tumor growth of pancreatic cancer by targeting SREBP1 and lipid synthesis